Maximizing cost savings and clinical outcomes of meropenem_dataset

A retrospective observational study was conducted in a tertiary-care private hospital in Saudi Arabia between April 2022 and December 2023. Meropenem utilization was assessed quarterly based on predefined key indicators to evaluate compliance with antimicrobial stewardship guidelines; Q1-2022 served as a baseline for comparison. Consumption was measured in defined daily doses (DDD) per 1,000 patient-days, and cost analysis was performed using Antimicrobial Cost Per Patient Day (ACPD). The main outcome measures included clinical improvement within 72 hours and transfer or discharge in good clinical condition. The data showed significant improvement in several clinical outcome indicators as well as reduction in meropenem cost. 1000